Content about Educational psychology

February 27, 2014

A long-term study by UCLA, in collaboration with the University of Aarhus in Denmark, has raised concerns about the use of acetaminophen during pregnancy, UCLA announced earlier this week.

LOS ANGELES — A long-term study by UCLA, in collaboration with the University of Aarhus in Denmark, has raised concerns about the use of acetaminophen during pregnancy, UCLA announced earlier this week.  

In a report in the current online edition of JAMA Pediatrics, researchers from the UCLA Fielding School of Public Health show that taking acetaminophen during pregnancy is associated with a higher risk in children of attention-deficity/hyperactivity disorder and hyperkinetic disorder.  

July 11, 2013

The Food and Drug Administration has approved a Kremers Urban Pharmaceuticals drug for treating attention deficit hyperactivity disorder, the UCB subsidiary said.

PRINCETON, N.J. — The Food and Drug Administration has approved a Kremers Urban Pharmaceuticals drug for treating attention deficit hyperactivity disorder, the UCB subsidiary said.

KU announced the approval of methylphenidate hydrochloride extended-release tablets in the 18-mg and 27-mg strengths.

The drug is a generic version of Johnson & Johnson's Concerta QD.

May 30, 2013

Drugs for attention deficit hyperactivity disorder don't appear to increase children's risk of abusing drugs and alcohol later in life, according to a new study.

NEW YORK — Drugs for attention deficit hyperactivity disorder don't appear to increase children's risk of abusing drugs and alcohol later in life, according to a new study.

April 2, 2013

More than one-tenth of school-age children and nearly one-fifth of high school boys in the United States have received a diagnosis for attention deficit hyperactivity disorder, according to published reports.

NEW YORK — More than one-tenth of school-age children and nearly one-fifth of high school boys in the United States have received a diagnosis for attention deficit hyperactivity disorder, according to published reports.

The New York Times reported that the dramatic rise in the number of children diagnosed with ADHD over the last decade could lead to concern of over-diagnosis of the condition, as well as overuse of medications to treat it. The Times based its report on an analysis of raw data from the Centers for Disease Control and Prevention.

February 15, 2013

The Food and Drug Administration has approved a generic drug for attention deficit hyperactivity disorder made by Teva Pharmaceutical Industries, the Israeli generic drug maker said.

JERUSALEM — The Food and Drug Administration has approved a generic drug for attention deficit hyperactivity disorder made by Teva Pharmaceutical Industries, the Israeli generic drug maker said.

September 14, 2012

Two generic drug makers have settled with a subsidiary of Johnson & Johnson and another company concerning a drug used to treat attention deficit hyperactivity disorder.

HAYWARD, Calif. — Two generic drug makers have settled with a subsidiary of Johnson & Johnson and another company concerning a drug used to treat attention deficit hyperactivity disorder.

Impax Labs and Teva Pharmaceuticals USA had settled a patent infringement suit with Janssen Pharmaceuticals and Alza over Concerta (methylphenidate hydrochloride) extended-release tablets in the 18-mg, 27-mg, 36-mg and 54-mg strengths.

September 12, 2012

Drug maker Shire is seeking Food and Drug Administration approval for a new usage for a drug used to treat attention deficit hyperactivity disorder, the company said Wednesday.

PHILADELPHIA — Drug maker Shire is seeking Food and Drug Administration approval for a new usage for a drug used to treat attention deficit hyperactivity disorder, the company said Wednesday.

Shire announced that the FDA had accepted its regulatory approval application for Vyvanse (lisdexamfetamine dimesylate) capsules for maintenance treatment of ADHD in patients ages 6 to 17 years. There currently are no stimulants approved for maintenance treatment of the condition in that age group, Shire said, and the FDA said it would complete its review by April 2013.

June 18, 2012

Top-level executives from more than a dozen major U.S. companies on Monday joined with government officials to launch a nationwide public-private sector initiative to advance employment of people with disabilities.

WINDSOR, Conn. — Top-level executives from more than a dozen major U.S. companies on Monday joined with government officials to launch a nationwide public-private sector initiative to advance employment of people with disabilities. The companies and officials plan to work together to achieve common goals, including to identify and resolve employment barriers facing people with disabilities, share experience and best practices, raise visibility around the effort and awareness of the significant benefits, and expand participation.

May 20, 2010

British drug maker Shire presented late-stage clinical study data at a psychiatric meeting Friday indicating...